Quanterix Corporation (QTRX)

NGM – Real vaqt narxi. Valyuta: USD

2.91

+0.11 (3.93%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript

06.05.2026

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.53 per share a year ago.

06.05.2026

Quanterix Releases Financial Results for the First Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. “We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition,” said Everett Cunningham, President & CEO of Quanterix. “As part.

06.05.2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.

24.04.2026

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. T.

17.04.2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone recep.

15.04.2026

Quanterix Debuts Content Innovation Engine at AACR 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a sys.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Quanterix Releases Financial Results for the First Quarter of 2026

06.05.2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

17.04.2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

15.04.2026

Quanterix Corporation (QTRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Quanterix Corporation (QTRX)

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Videolar

No Data

Press-relizlar

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Videolar

No Data

Press-relizlar

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Search stocks

Quanterix Corporation (QTRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Quanterix Corporation (QTRX)

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Videolar

No Data

Press-relizlar

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026

Videolar

No Data

Press-relizlar

Quanterix Releases Financial Results for the First Quarter of 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Quanterix Debuts Content Innovation Engine at AACR 2026